Evidence map›Paper›PMID 41721853›Full record

ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026

The CAPA framework: a conceptual model integrating corrective and preventive strategies for retinal ischemia and neovascularization.

Ramesh Venkatesh, Vishma Prabhu, Pratibha Hande, Chaitra Jayadev, Rupak Roy, Rohit Shetty, Soema Tebhla, Pragati Raj, Madhav Pai, Karishma Tendulkar and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ramesh VenkateshDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India. vramesh80@yahoo.com.ORCID 0000-0002-4479-9390
Vishma PrabhuDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Pratibha HandeDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Chaitra JayadevDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Rupak RoyDepartment of Vitreo-retina, Aditya Birla Sankara Nethralaya, Kolkata, India.
Rohit ShettyDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Soema TebhlaDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Pragati RajDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Madhav PaiDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Karishma TendulkarDepartment of Vitreo-retina, Narayana Nethralaya, Bangalore, India.
Jay ChhablaniDepartment of Medical Retina and Vitreoretinal Surgery, UPMC, Pittsburg, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal ischemia remains a leading cause of irreversible blindness worldwide and underlies major conditions such as diabetic retinopathy, retinal vein occlusion, ocular ischemic syndrome, retinopathy of prematurity, and retinal vasculitis. Current management strategies are often fragmented and reactive, with panretinal photocoagulation (PRP), intravitreal anti–vascular endothelial growth factor (VEGF) therapy, and pars plana vitrectomy (PPV) commonly initiated only after sight-threatening neovascular complications have developed. This narrative review synthesizes evidence from landmark clinical trials, meta-analyses, and multimodal imaging studies identified through PubMed, Scopus, Web of Science, and Google Scholar (1980–2025). We propose the Corrective Action and Preventive Action (CAPA) framework as a stage-specific conceptual model that integrates corrective interventions—such as anti-VEGF therapy, focal laser, and PPV—with preventive strategies, including PRP and targeted ischemic bed ablation, guided by widefield fluorescein angiography, optical coherence tomography (OCT), and OCT angiography. By reframing timing and sequencing of treatment, the CAPA model aims to shift practice toward proactive and structured disease modification, with the goal of preserving vision earlier and reducing long-term sequelae. Prospective studies are needed to determine the safety, cost-effectiveness, and feasibility of implementing CAPA across diverse healthcare settings.

Indexed as

IschemiaLaser CoagulationRetinal DiseasesRetinal NeovascularizationVitrectomyAngiogenesis InhibitorsFluorescein AngiographyHumansTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor AAnti-VEGF therapyCAPA frameworkNeovascularizationPanretinal photocoagulationRetinal ischemia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.